Skip to main content
Jasper Therapeutics, Inc. logo

Jasper Therapeutics, Inc. — Investor Relations & Filings

Ticker · JSPR ISIN · US4718712023 US Professional, scientific and technical activities
Open in API
Filings indexed 422 across all filing types
Latest filing 2020-12-03 Regulatory Filings
Country US United States of America
Listing US JSPR

About Jasper Therapeutics, Inc.

https://jaspertx.com/

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company that develops therapies targeting mast and hematopoietic stem cells. The company's lead product candidate is briquilimab, a monoclonal antibody that targets c-Kit (CD117). This therapeutic is designed to deplete mast cells for the treatment of chronic immunological and inflammatory diseases. Jasper Therapeutics is conducting clinical studies to evaluate briquilimab in patients with chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. The company's mission is to provide safer and more effective therapies for patients with chronic mast cell-driven diseases.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report under the Securities Exchange Act of 1934. The content focuses on the announcement of the date and details of the company's 2020 Annual Meeting of Stockholders, including procedures for shareholder proposals and director nominations. There is no financial data, earnings information, or detailed report content. The document is an announcement of an event related to governance and shareholder meetings, but it is not the actual proxy statement or annual report. Given the nature of the content, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories like Proxy Solicitation or Annual Report. The document length is just over 5,000 characters but contains no substantive financial or report data, confirming it is an 8-K announcement rather than a full report or presentation.
2020-12-03 English
QUARTERLY REPORT
Interim / Quarterly Report Q3 2020
2020-11-10 English
PRIMARY DOCUMENT
Director's Dealing
2020-09-23 English
PRIMARY DOCUMENT
Director's Dealing
2020-09-18 English
PRIMARY DOCUMENT
Director's Dealing
2020-09-15 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-09-10 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.